Use of Hydroxyurea in Pediatric Patients with Sickle Cell Disease
About:
CLINICAL PRACTICE GUIDELINE SERIES.
Hydroxyurea is a myelosuppressive agent that has become a standard therapy for both pediatric and adult patients with sickle cell anemia (SCA), genotypes HbSS and HbSβ0, regardless of disease severity. 1 For pediatric patients, hydroxyurea has an acceptable short- term toxicity profile with the main side effect being mild, transient and reversible myelosuppression…
More Information:
